Allogene Therapeutics Inc (NASDAQ: ALLO) has seen a decline in its stock price by -6.68 in relation to its previous close of 2.17. However, the company has experienced a -0.74% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-13 that SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) as a Rapid Communication in the Journal of Clinical Oncology. These results represent the largest dataset of LBCL patients treated with an allogeneic CAR T product and, with a minimum of two years of follow-up, the longest follow-up to date.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
Moreover, the 36-month beta value for ALLO is 1.02. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 4 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for ALLO is 134.72M and currently, short sellers hold a 23.79% of that float. On February 24, 2025, ALLO’s average trading volume was 5.14M shares.
ALLO’s Market Performance
ALLO stock saw an increase of -0.74% in the past week, with a monthly gain of 7.71% and a quarterly increase of -4.48%. The volatility ratio for the week is 38.09%, and the volatility levels for the last 30 days are 15.08% for Allogene Therapeutics Inc (ALLO). The simple moving average for the last 20 days is 9.14% for ALLO stock, with a simple moving average of -17.44% for the last 200 days.
Analysts’ Opinion of ALLO
Many brokerage firms have already submitted their reports for ALLO stocks, with Oppenheimer repeating the rating for ALLO by listing it as a “Outperform.” The predicted price for ALLO in the upcoming period, according to Oppenheimer is $11 based on the research report published on August 08, 2024 of the previous year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALLO reach a price target of $11. The rating they have provided for ALLO stocks is “Overweight” according to the report published on May 31st, 2024.
ALLO Trading at 3.34% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.94% of loss for the given period.
Volatility was left at 15.08%, however, over the last 30 days, the volatility rate increased by 38.09%, as shares surge +6.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.29% lower at present.
During the last 5 trading sessions, ALLO rose by +0.94%, which changed the moving average for the period of 200-days by -31.59% in comparison to the 20-day moving average, which settled at $1.86. In addition, Allogene Therapeutics Inc saw -4.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from MESSEMER DEBORAH M., who sale 13,313 shares at the price of $2.43 back on Feb 18 ’25. After this action, MESSEMER DEBORAH M. now owns 144,316 shares of Allogene Therapeutics Inc, valued at $32,351 using the latest closing price.
MESSEMER DEBORAH M., the Director of Allogene Therapeutics Inc, proposed sale 13,313 shares at $2.43 during a trade that took place back on Feb 18 ’25, which means that MESSEMER DEBORAH M. is holding shares at $32,329 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -6501.95 for the present operating margin
- -1437.6 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -6591.37. The total capital return value is set at -0.5. Equity return is now at value -54.15, with -43.56 for asset returns.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -2.55. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -599.97.
Currently, EBITDA for the company is -300.29 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 11052.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.35.
Conclusion
To wrap up, the performance of Allogene Therapeutics Inc (ALLO) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
